View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Editas Medicine Announces First Quarter 2024 Results Conference Call a...

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial and international callers should dial approximately five minutes before the call begins.Participants should ask to be c...

 PRESS RELEASE

Carriage Services Announces First Quarter 2024 Results

Carriage Services Announces First Quarter 2024 Results Conference call on Thursday, May 2, 2024 at 9:30 a.m. central time HOUSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Carriage Services, Inc. (NYSE: CSV) today announced its financial results for the first quarter ended March 31, 2024. Company Highlights: Total revenue of $103.5 million led to growth of 8.4% over the prior-year quarter, primarily driven by a 38.4% increase in cemetery preneed sales;GAAP diluted EPS of $0.45 and Adjusted diluted EPS of $0.75, compared to $0.57 and $0.56 in the prior-year quarter, respectively;Completed the ...

 PRESS RELEASE

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Coll...

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimm...

 PRESS RELEASE

Streamline Health® Reports Fiscal Fourth Quarter and Full Year 2023 Fi...

Streamline Health® Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results 14% growth of SaaS revenue in fiscal 2023 compared to fiscal 2022$0.4 million of adjusted EBITDA generated in the fourth quarter of fiscal 2023 compared to ($0.2 million) during the fourth quarter of fiscal 2022; $2.4 million of adjusted EBITDA improvement in fiscal 2023 vs. fiscal 2022($1.4 million) net loss during the fourth quarter of fiscal 2023, compared to ($2.2 million) during the fourth quarter of fiscal 2022$15.0 million of Booked SaaS ACV as of January 31, 2024; $15.6 million of Booked SaaS ACV a...

 PRESS RELEASE

Streamline Health® Expands eValuator™ Footprint With Existing Client

Streamline Health® Expands eValuator™ Footprint With Existing Client Following an efficient implementation process, a leading Florida-based healthcare provider is expanding its footprint and utilization of eValuator Atlanta, GA, April 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its existing contract with a 1,250 bed, Epic-based academic medical center serving central Florida. The health system recently completed its initial implementation of eValuator and ha...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: April 29, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Antoine Legault ... (+2)
  • Antoine Legault
  • Gerald Pascarelli
 PRESS RELEASE

Streamline Health® Signs Second Enterprise Client

Streamline Health® Signs Second Enterprise Client 700-Bed health system adds eValuator™, becomes second healthcare provider leveraging both eValuator and RevID to improve revenue integrity pre-bill Atlanta, GA, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its partnership with a 5 facility, 700-bed Oracle EHR based health system. The system has been using RevID’s automated charge reconciliation for more than 2 years and has elected to add eValuator’s c...

 PRESS RELEASE

Editas Medicine to Present Pre-clinical Data Demonstrating Progression...

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to ...

 PRESS RELEASE

Streamline Health® To Report Fourth Quarter and Fiscal Year 2023 Finan...

Streamline Health® To Report Fourth Quarter and Fiscal Year 2023 Financial Performance Atlanta, GA, April 22, 2024 (GLOBE NEWSWIRE) --  (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced that it will release its financial results for the three and twelve month periods ended January 31, 2024 on Monday April 29, 2024 after the close of the financial markets. The Company will conduct a conference call on Tuesday, April 30, 2024, at 9:00 AM E...

Antoine Legault ... (+2)
  • Antoine Legault
  • Gerald Pascarelli
 PRESS RELEASE

Carriage Services Declares Quarterly Cash Dividend

Carriage Services Declares Quarterly Cash Dividend HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Carriage Services, Inc. (NYSE: CSV) today announced that its Board of Directors on April 18, 2024 declared a quarterly dividend of 11.25¢ per share payable on June 3, 2024 to common share record holders as of May 6, 2024. Carriage Services is a leading provider of funeral and cemetery services and merchandise in the United States. Carriage Services operates 165 funeral homes in 26 states and 31 cemeteries in 11 states. For more information, please email .  

 PRESS RELEASE

Carriage Services Announces 2024 First Quarter Earnings Release and Co...

Carriage Services Announces 2024 First Quarter Earnings Release and Conference Call Schedule HOUSTON, April 17, 2024 (GLOBE NEWSWIRE) -- Carriage Services, Inc. (NYSE: CSV) today announced plans to release 2024 first quarter results on Wednesday, May 1, 2024 after the market closes. In conjunction with the release, Carriage Services has scheduled a conference call, which will be broadcast live over the Internet on Thursday, May 2, 2024 at 9:30 a.m. central time. What:Carriage Services First Quarter 2024 Earnings Conference CallWhen:Thursday, May 2, 2024 – 9:30 a.m. central time How:Live v...

Carriage Services Inc: 1 director

A director at Carriage Services Inc bought 6,000 shares at 25.580USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: March 7, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch